

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi.
We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 23-C-055**

Please note that this information covers the period January to March 2023.

You asked:

1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

Ipilimumab (monotherapy)	0
Nivolumab (monotherapy)	<5
Nivolumab AND Ipilimumab (combination)	<5
Pembrolizumab	<5
Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)	5
Other active systemic anti-cancer therapy	<5

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma?

Avelumab + Axitinib	0
Nivolumab	0
Nivolumab + Cabozantinib	0
Nivolumab + Ipilimumab	<5

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**



3. In the past 3 months, how many patients have been initiated* on the following agents for treatment of Oesophageal Cancer:

Nivolumab monotherapy or in combination with Ipilimumab	<5
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	<5
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

